BRKR Stock Analysis: Bruker | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 9.383m USD | 12M Return: 38.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 127M
EPS Trend: -91.1%
Qual. Beats: 1
Rev. Trend: 94.1%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bruker Corporation is a U.S.-based manufacturer of scientific instruments and analytical and diagnostic solutions, organized into four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. Its product portfolio spans magnetic resonance spectroscopy (NMR and EPR), mass spectrometry, molecular diagnostics kits, X-ray and fluorescence instrumentation, atomic force microscopy, optical fluorescence microscopy, and superconducting materials and wires, supported by service, lifecycle, and lab automation offerings. The company was founded in 1960 and is headquartered in Billerica, Massachusetts, and trades on NASDAQ under the ticker BRKR.
The company sits in the Life Sciences Tools & Services sub-industry within Health Care, supplying research, analytical, and process instruments primarily to pharmaceutical, biotechnology, academic, government, and industrial customers. Its business model combines capital equipment sales with recurring revenue from consumables, aftermarket services, and lifecycle support tied to its installed base of advanced analytical systems.
- Nano segment growth driven by semiconductor metrology demand
- Biopharma and proteomics demand supports BioSpin and CALID revenue
- China weakness and FX headwinds pressure reported organic growth
| Net Income: -11.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -2.11 > 1.0 |
| NWC/Revenue: 21.64% < 20% (prev 22.25%; Δ -0.60% < -1%) |
| CFO/TA 0.02 > 3% & CFO 140.3m > Net Income -11.6m |
| Net Debt (1.71b) to EBITDA (302.7m): 5.65 < 3 |
| Current Ratio: 1.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (152.7m) vs 12m ago 0.53% < -2% |
| Gross Margin: 45.56% > 18% (prev 48.98%; Δ -3.42% > 0.5%) |
| Asset Turnover: 57.34% > 50% (prev 58.08%; Δ -0.75% > 0%) |
| Interest Coverage Ratio: 1.25 > 6 (EBIT TTM 74.5m / Interest Expense TTM 59.4m) |
| A: 0.12 (Total Current Assets 2.10b - Total Current Liabilities 1.36b) / Total Assets 6.13b |
| B: 0.38 (Retained Earnings 2.36b / Total Assets 6.13b) |
| C: 0.01 (EBIT TTM 74.5m / Avg Total Assets 6.03b) |
| D: 0.68 (Book Value of Equity 2.45b / Total Liabilities 3.63b) |
| Altman-Z'' = 2.85 = A |
| DSRI: 1.07 (Receivables 750.4m/701.1m, Revenue 3.46b/3.45b) |
| GMI: 1.07 (GM 48.98% / 45.56%) |
| AQI: 1.02 (AQ_t 0.54 / AQ_t-1 0.53) |
| SGI: 1.00 (Revenue 3.46b / 3.45b) |
| TATA: -0.02 (NI -11.6m - CFO 140.3m) / TA 6.13b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 60.06 with a total of 1,110,611 shares traded. Over the past week, the price has changed by -2.56%, over one month by +9.46%, over three months by +59.92% and over the past year by +38.50%.
Current recommended Stop Loss: 52.30 (which is 12.9% or 2.8 ATR below the current price).
Bruker has received a consensus analysts rating of 3.86. Therefore, it is recommended to buy BRKR.
- StrongBuy: 5
- Buy: 2
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 53.8 | -10.4% |
P/E Forward = 15.2207
P/S = 2.7131
P/B = 3.8313
P/EG = 1.5155
Revenue TTM = 3.46b USD
EBIT TTM = 74.5m USD
EBITDA TTM = 302.7m USD
Long Term Debt = 1.66b USD (from longTermDebt, last quarter)
Short Term Debt = 8.40m USD (from shortTermDebt, last quarter)
Debt = 1.85b USD (from shortLongTermDebtTotal, last quarter) + Leases 173.8m
Net Debt = 1.71b USD (calculated: Debt 1.85b - CCE 133.4m)
Enterprise Value = 11.1b USD (9.38b + Debt 1.85b - CCE 133.4m)
Interest Coverage Ratio = 1.25 (Ebit TTM 74.5m / Interest Expense TTM 59.4m)
EV/FCF = 216.3x (Enterprise Value 11.1b / FCF TTM 51.3m)
FCF Yield = 0.46% (FCF TTM 51.3m / Enterprise Value 11.1b)
FCF Margin = 1.48% (FCF TTM 51.3m / Revenue TTM 3.46b)
Net Margin = -0.34% (Net Income TTM -11.6m / Revenue TTM 3.46b)
Gross Margin = 45.56% ((Revenue TTM 3.46b - Cost of Revenue TTM 1.88b) / Revenue TTM)
Gross Margin QoQ = 47.28% (prev 45.97%)
Tobins Q-Ratio = 1.81 (Enterprise Value 11.1b / Total Assets 6.13b)
Interest Expense / Debt = 3.22% (Interest Expense 59.4m / Debt 1.85b)
Taxrate = 13.74% (2.50m / 18.2m)
NOPAT = 64.3m (EBIT 74.5m * (1 - 13.74%))
Current Ratio = 1.55 (Total Current Assets 2.10b / Total Current Liabilities 1.36b)
Debt / Equity = 0.75 (Debt 1.85b / totalStockholderEquity, last quarter 2.45b)
Debt / EBITDA = 5.65 (Net Debt 1.71b / EBITDA 302.7m)
Debt / FCF = 33.37 (Net Debt 1.71b / FCF TTM 51.3m)
Total Stockholder Equity = 2.29b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.19% (Net Income -11.6m / Total Assets 6.13b)
RoE = -0.51% (Net Income TTM -11.6m / Total Stockholder Equity 2.29b)
RoCE = 1.89% (EBIT 74.5m / Capital Employed (Equity 2.29b + L.T.Debt 1.66b))
RoIC = 1.38% (NOPAT 64.3m / Invested Capital 4.65b)
WACC = 10.07% (E(9.38b)/V(11.2b) * Re(11.51%) + D(1.85b)/V(11.2b) * Rd(3.22%) * (1-Tc(0.14)))
Discount Rate = 11.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 58.43 | Cagr: 2.01%
[DCF] Terminal Value 66.93% ; FCFF base≈100.6m ; Y1≈88.2m ; Y5≈71.3m
[DCF] Fair Price = N/A (negative equity: EV 891.9m - Net Debt 1.71b = -819.8m; debt exceeds intrinsic value)
EPS Correlation: -91.09 | EPS CAGR: -13.62% | SUE: 1.12 | # QB: 1
Revenue Correlation: 94.14 | Revenue CAGR: 9.53% | SUE: 2.28 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.38 | Chg30d=-0.70% | Revisions=-17% | Analysts=12
EPS next Quarter (2026-09-30): EPS=0.55 | Chg30d=+0.36% | Revisions=+40% | Analysts=12
EPS current Year (2026-12-31): EPS=2.12 | Chg30d=-0.01% | Revisions=+7% | GrowthEPS=+15.7% | GrowthRev=+4.4%
EPS next Year (2027-12-31): EPS=2.44 | Chg30d=+0.79% | Revisions=-21% | GrowthEPS=+15.1% | GrowthRev=+4.2%
[Analyst] Revisions Ratio: -3% (up=13, down=14)